| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3982921 | Clinical Radiology | 2008 | 13 Pages |
Abstract
Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[fluorine-18] fluoro-2-deoxy-d-glucose (FDG) is now established in the management of oncology patients. With increasing availability and a constantly advancing body of evidence, the role of FDG PET/CT in oesophageal cancer is set to expand to include initial staging, assessment of disease response, therapy planning, and detection of disease recurrence. This article reviews the utility of FDG PET/CT in the management of oesophageal carcinoma, discussing its role and limitations in the imaging of these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
F.U. Chowdhury, K.M. Bradley, F.V. Gleeson,